BioVie says bezisterim shows distinct responses in two Long COVID patient groups
BioVie Inc. reported Phase 2 trial results showing bezisterim had distinct effects on two Long COVID patient groups. High-inflammatory patients improved in cognition, while low white blood cell patients saw fatigue and post-exertional malaise reductions. Bezisterim also lowered NPY levels by 33%. The trial involved 203 participants.
How this was made

The 30-second read
Why it matters
Traders may reassess bezisterim’s development path toward more targeted future trials, using inflammatory biomarkers for cognition and low WBC/myeloid profiles for fatigue and post-exertional malaise.
Market read
The article provides new subgroup effect differentiation and biomarker response signals, which can shift expectations for future trial design despite overall non-significance.
What to watch
NPY is being added to NIH RECOVER prioritization, but the article stresses it is not yet validated as a diagnostic or predictive biomarker, which could slow translation into trial-ready selection criteria.
Background
BioVie’s ADDRESS-LC Phase 2 trial evaluated bezisterim in Long COVID and now presents biomarker-defined subgroup analyses at a Long COVID conference.
Ticker impact
BioVie reports Phase 2 ADDRESS-LC exploratory analyses showing two biomarker-defined Long COVID groups respond differently to bezisterim.
Likely modest upside bias as traders price improved probability of future trial success via endotype targeting, tempered by the lack of overall statistical significance.
The article discloses subgroup effect sizes and biomarker-linked endpoint differentiation, plus safety/tolerability comparable to placebo, but explicitly notes the overall population trend did not reach statistical significance.
Market effects
Reinforces the broader Long COVID biotech playbook of biomarker-defined endotypes and endpoint tailoring, which can influence sentiment across the sector.
Limited direct impact beyond US biotech sentiment, since the catalyst is company-specific clinical-trial subgroup analysis.
Moderate relevance for international Long COVID research stakeholders, but unlikely to move global risk appetite.
Counterpoint
Because the findings are exploratory and the overall population did not achieve statistical significance, the market may overestimate the durability of the subgroup signals.
Key entities
- companyBioVie Inc
NASDAQ-listed biotech running Phase 2 ADDRESS-LC for bezisterim in Long COVID.
- drugbezisterim
BioVie’s investigational therapy evaluated in ADDRESS-LC.
- clinical_trialADDRESS-LC
Phase 2 randomized trial of bezisterim versus placebo for 12 weeks in Long COVID.
- biomarkerNPY (neuropeptide Y)
Circulating biomarker reduced by bezisterim by about 33% at Week 12; added to NIH RECOVER prioritization list.


